Are Specialty Drugs Worth the Money?

People suffering from any number of serious diseases, including multiple sclerosis, central nervous system disorders, Hepatitis C, pulmonary hypertension, cancer or HIV know their drugs are costly—very costly. In 2014, specialty drugs accounted for less than 1% of all prescriptions, but for about 32% of all prescription drug spending. They can be up to 50 times more expensive than traditional drugs. So, are they worth the astronomical cost?

A peer-reviewed academic study in the journal Health Affairs tried to suss out exactly that—do new drugs offer significantly better value than existing drugs or non-drug treatments for a specific health condition? And do new specialty drugs offer value for the money spent compared with the cost of traditional drugs?

Researchers found that specialty drugs in particular were associated with significant improvements in terms of good health over time. The authors claimed, “Our study suggests that although specialty drugs often have higher costs than traditional drugs, they also tend to confer greater benefits and hence may still offer reasonable value for money.”

Researchers also said that for many of the aforementioned diseases, there were no or very few effective drugs to treat them, so the benefits conferred on the patient are not surprising.

On the flip side, paying for these drugs, some of which can run $3,000 a month or more, is a major hurdle. Insurance companies are struggling with the heavy burden of costs, and some plans now require patients to pay up to 50% of the cost of the drug out of pocket.  Many patients, desperate for a cure or a better quality of life, are finding a way to pay for the specialty drugs or going into significant debt.

Self-funded plans should be aware that specialty drugs are on the rise.  For now, there is no lifetime maximum of coverage for employer contributions, whereas the employee has an annual out-of-pocket maximum, so the costs for an employee’s health coverage in a self-funded plan could mount to significant totals.

Here are three actions a self-funded plan can take to mitigate risks from specialty drug costs:

  • Consider what risk level you are willing to take and review your plan documents to be sure that your coverage is in line with your philosophy.
  • Look at your plan to consider changes to co-pays or stop loss deductible levels.
  • Discuss the cost of the drugs with the pharmacy benefit manager. Often, additional discounts are available to reduce the cost.

As always, contact us with any questions on this topic or to discuss your stop loss insurance coverage.

Newsletter Signup

Signup to start receiving the latest newsletters from StopLoss right to your email.
Stay up to date on insurance trends and insights.

Back to Top

In 2011, the top 5 most expensive medical conditions treated in US hospitals were: Septicemia, Osteoarthritis, Complication of device, implant or graft, Liveborn, and Acute myocardial infarction

From 2010 to 2013, the number of claims that were individually $1 million or above rose by 1,000%

In 2017 approximately 18% of the American public will purchase insurance through exchanges, radically transforming the health insurance landscape.

In 2014, 98% of large firms (= 200 Workers) offer 1+ wellness programs to their employees.

The most costly 1% of patients account for 20% of national health expenditures – accruing average annual expenses of nearly $90,000 per person.

6% of firms offering fully-insured plans report they intend to self-insure because of Obamacare.

In 2014, PPO plans remained the most common plan type, enrolling 58% of covered workers.

In 2012, 93% of businesses with 5,000+ employees and 80% of companies with 1,000-4,999 employees were self-funded

Massachusetts has the third-highest prevalence of self-funded insurance in the small-group market (Fewer than 50 employees).

In 2013, the average deductible was $2,906 for individuals selecting plans from marketplaces. This compares with average deductibles of $1,135 for an individual with employer coverage.

In 2013, the average annual premiums for employer-sponsored health insurance are $5,884 for single coverage and $16,351 for family coverage, up 5% and 4% respectively from 2012.

From 2010 – 2013, cancer followed by chronic/end stage renal disease and leukemia accounted for the top 3 costliest illnesses.